Chinese firm to start trials of COVID drug proxalutamide in PH in November
Image from Kintor Pharmaceuticals, makers of COVID-19 drug proxalutamide.
MANILA, Philippines — Chinese biotech firm Kintor Pharmaceutical Limited plans to conduct clinical trials in the Philippines for its experimental drug for COVID-19 called proxalutamide that is also being developed to treat prostate and breast cancer, the Department of Health (DOH) said Friday.
“Meron na pong nakasalang na magiging trial dito sa atin sa Pilipinas at they have identified the Lung Center of the Philippines for this. They are currently processing the contract,” Health Undersecretary Maria Rosario Vergeire told an online media briefing.
(There is already a trial to be conducted here in the Philippines and they have identified the Lung Center of the Philippines as a trial site. They are currently processing the contract.)
“Nandoon pa lang tayo sa contracting stage pero may nakalagay doon sa kanilang isinumite na protocol na they intend to start by November of this year,” Vergeire added.
(They are still in the contract stage but they stated in their submission that they intend to start by November of this year.)
Proxalutamide is a nonsteroidal antiandrogen that is under development for the potential treatment of COVID-19, prostate cancer, and breast cancer.
RELATED STORIES:
PH will work to ‘have better access’ to antiviral pill vs COVID-19 – DOH exec
Concerns over Chinese firm conducting trial for vaccine against COVID-19 in Cebu City
